We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
-6.71%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$5.79B
AUM Growth
-$16.3M
Cap. Flow
+$777M
Cap. Flow %
13.41%
Top 10 Hldgs %
69.76%
Holding
51
New
7
Increased
15
Reduced
5
Closed
5

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$308M
2
XLRN
Acceleron Pharma
XLRN
+$187M
3
FOLD
Amicus Therapeutics
FOLD
+$50.3M
4
DSGN icon
Design Therapeutics
DSGN
+$49.5M
5
APLS
Apellis Pharmaceuticals
APLS
+$47.3M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$300M
2
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$18.9M
3
ITOS
iTeos Therapeutics
ITOS
+$15.6M
4
TVTX icon
Travere Therapeutics
TVTX
+$15.2M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$10.8M

Sector Composition

Rank Sector Weight
1 Healthcare 93.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISEE
26
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$44.8M 0.77%
7,250,000
– –
APLS
27
DELISTED
Apellis Pharmaceuticals
APLS
$42.9M 0.74%
+1,000,000
New +$47.3M
DCPH
28
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$40M 0.69%
893,000
-407,000
-31% -$18.9M
DSGN icon
29
Design Therapeutics
DSGN
$862M
$39.7M 0.69%
+1,468,318
New +$49.5M
AVDL
30
DELISTED
Avadel Pharmaceuticals
AVDL
$39.5M 0.68%
4,365,000
– –
AMRN
31
Amarin Corp
AMRN
$301M
$37.3M 0.64%
300,000
– –
TVTX icon
32
Travere Therapeutics
TVTX
$5.89B
$31.2M 0.54%
1,249,000
-551,500
-31% -$15.2M
MNKD icon
33
MannKind Corp
MNKD
$1.25B
$29.4M 0.51%
7,500,000
+4,000,000
+114% +$16.4M
OLMA icon
34
Olema Pharmaceuticals
OLMA
$1.03B
$24.6M 0.42%
876,986
– –
ADAP
35
DELISTED
Adaptimmune Therapeutics
ADAP
$18.9M 0.33%
3,550,000
– –
RLAY icon
36
Relay Therapeutics
RLAY
$4.3B
$17.3M 0.3%
500,000
– –
MRUS
37
DELISTED
Merus
MRUS
$13.9M 0.24%
+665,000
New +$15.3M
GNCA
38
DELISTED
Genocea Biosciences, Inc.
GNCA
$13.8M 0.24%
5,084,184
– –
RNAM
39
DELISTED
Avidity Biosciences
RNAM
$11.9M 0.21%
545,000
– –
BDTX icon
40
Black Diamond Therapeutics
BDTX
$110M
$10.7M 0.18%
440,000
-200,000
-31% -$5.39M
PNT
41
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$10.5M 0.18%
1,000,000
– –
FENC icon
42
Fennec Pharmaceuticals
FENC
$377M
$10.4M 0.18%
1,670,000
– –
TNGX icon
43
Tango Therapeutics
TNGX
$4.72B
$8.9M 0.15%
800,000
– –
JNCE
44
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$5.7M 0.1%
+555,000
New +$6.08M
LKFT
45
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.71B
$239K ﹤0.01%
+3,100
New +$286K
ASND icon
46
Ascendis Pharma A/S
ASND
$16.4B
– –
-1,800,000
Closed -$300M
CUE icon
47
Cue Biopharma
CUE
$113M
– –
-15,083
Closed -$5.66M
ITOS
48
DELISTED
iTeos Therapeutics
ITOS
– –
-460,000
Closed -$15.6M
NKTR icon
49
CALL
Nektar Therapeutics
NKTR
$2.48B
– –
-6,667
Closed -$26K
ATNX
50
DELISTED
Athenex, Inc. Common Stock
ATNX
– –
-18,625
Closed -$4.12M
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q1 2021 Portfolio in Review

As of Q1 2021, Avoro Capital Advisors held 51 positions worth $5.79B, down 0.28% from $5.81B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Avoro Capital Advisors deployed $777M of net new capital in Q1 2021, opening 7 new positions and adding to 15 existing holdings. Its largest new stake was Vertex Pharmaceuticals: 1,400,000 shares worth $301M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 98% a quarter earlier.

On the sell side, the largest reduction was Deciphera Pharmaceuticals, Inc. Common Stock, an estimated $18.9M trimmed.

  • Avoro Capital Advisors's largest Q1 2021 buy was Vertex Pharmaceuticals: 1,400,000 shares worth $301M.
  • Avoro Capital Advisors added most to Acceleron Pharma in Q1 2021, an estimated $187M increase.
  • Avoro Capital Advisors's biggest Q1 2021 reduction was Deciphera Pharmaceuticals, Inc. Common Stock, cutting an estimated $18.9M.
  • Avoro Capital Advisors fully exited Ascendis Pharma A/S in Q1 2021, selling an estimated $300M.
  • Avoro Capital Advisors's ten largest holdings make up 70% of its $5.79B portfolio in Q1 2021.
  • Avoro Capital Advisors opened 7 new positions and closed 5 in Q1 2021.
  • Avoro Capital Advisors's portfolio value fell 0.28% quarter-over-quarter to $5.79B.

Based on Avoro Capital Advisors's 13F filing for Q1 2021, filed 17 May 2021.